Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis
- 3 March 2011
- journal article
- research article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 28 (4) , 405-411
Abstract
We retrospectively analyzed treatment outcomes and factors for poor prognosis for patients with renal cell cancer (RCC) bone metastases. Patients with bone metastases at initial diagnosis of metastasis secondary from RCC, treated at our hospital between 1984 and 2009, were retrospectively reviewed and statistically analyzed. Among 214 RCC patients with metastasis, 71 patients (33%) were found to have bone metastases at initial diagnosis of metastasis. The median follow-up was 21.1 months (intra-quartile range: IQR, 9.1–47.4 months). The estimated median overall survival time from the diagnosis of bone metastasis was 27.7 months. The probability of patients surviving at 1, 2, and 5 years was 63.7, 52.2, and 19.3%, respectively. When they were stratified by MSKCC scores, the probability of the median overall survival of the populations classified as favorable, intermediate, and poor was not reached, 32.9, and 10.5 months, respectively (P = 0.002). In addition, poor performance status (PS) (hazard ratio [HR]: 1.938, P = 0.035) and no prior nephrectomy (HR: 3.008, P = 0.004) were extracted as independent poor prognostic factors by multivariate analysis. All treatment modalities—including radical en bloc surgery, radiation therapy, cytokine therapy, molecular targeted therapy, and administration of zoledronic acid—seemed to contribute to favorable survival. More than half of the patients with bone metastases secondary from RCC were predicted to survive more than 24 months. In this population, MSKCC scores were valid predictors of survival. With increased treatment options, RCC patients with bone metastasis may benefit further from subsequent modalities and/or agents.Keywords
This publication has 25 references indexed in Scilit:
- Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinomaAnnals of Oncology, 2011
- Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell CarcinomaJapanese Journal of Clinical Oncology, 2010
- Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialThe Lancet Oncology, 2010
- Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors modelBMC Cancer, 2010
- Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastasesJournal of Cancer Research and Clinical Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapyCancer, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- A phase II trial of palliative radiotherapy for metastatic renal cell carcinomaCancer, 2005
- Current aspects of the surgical management of organ‐confined, metastatic, and recurrent renal cell cancerBJU International, 2005